| First Author | Dallas SL | Year | 1999 |
| Journal | Blood | Volume | 93 |
| Issue | 5 | Pages | 1697-706 |
| PubMed ID | 10029599 | Mgi Jnum | J:53331 |
| Mgi Id | MGI:1332306 | Doi | 10.1182/blood.v93.5.1697.405a17_1697_1706 |
| Citation | Dallas SL, et al. (1999) Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood 93(5):1697-706 |
| abstractText | We determined the effects of the potent bisphosphonate ibandronate in a murine model of human myeloma bone disease. In this model, bone lesions typical of the human disease develop in mice following inoculation of myeloma cells via the tail vein. Treatment with ibandronate (4 micrograms per mouse per day) significantly reduced the occurrence of osteolytic bone lesions in myeloma-bearing mice. However, ibandronate did not prevent the mice from developing hindlimb paralysis and did not produce a detectable effect on survival. There was no significant effect of ibandronate on total myeloma cell burden, as assessed by morphometric measurements of myeloma cells in the bone marrow, liver, and spleen, or by measurement of serum IgG2b levels. These results support clinical findings that bisphosphonates may be useful for the treatment of myeloma-associated bone destruction, but suggest that other therapies are also required to reduce tumor growth. |
